Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Trizivir

Executive Summary

Direct-to-consumer campaign for HIV therapy Trizivir will begin shortly, company says. Trizivir - a triple combination of abacavir, lamivudine and zidovudine - is cited as a "possible exception" in an FDA advisory that DTC ads should emphasize that HIV therapies "should be taken only in combination with other drugs for HIV infection." Some DTC campaigns display images "not representative of HIV infection," and fail to show limitations of HIV therapies prominently, FDA advisory letter states. The letter, signed by FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams, was sent April 27 to eight HIV drug makers, who have 90 days to revise materials

You may also be interested in...



FDA Cites Abbott’s Humira Psoriasis Ad: Patient Does Not Exhibit Severe Disease

Warning letter for Humira ad reprises agency interest in clear identification of appropriate patients.

Patient Testimonials Must Be “Typical” For Rx, FDA’s Ostrove Says

Patient testimonials in prescription drug ads should illustrate "typical" experiences among patients on the medication, FDA Division of Drug Marketing, Advertising & Communications Deputy Director Nancy Ostrove, PhD, told a Food & Drug Law Institute conference Oct. 17 in Washington, D.C

Patient Testimonials Must Be “Typical” For Rx, FDA’s Ostrove Says

Patient testimonials in prescription drug ads should illustrate "typical" experiences among patients on the medication, FDA Division of Drug Marketing, Advertising & Communications Deputy Director Nancy Ostrove, PhD, told a Food & Drug Law Institute conference Oct. 17 in Washington, D.C

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel